IAVI P002
Status:Completed
Phase:I
Principal Investigator(s):Brian Gazzard
Objective:This trial will study a prime-boost vaccine approach designed mainly to induce cell-mediated immune (CTL) responses.
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
DescriptionADVAX at 0,1 and 2 months followed by TBC-M4 at 6 months
Mode of DeliveryBiojector, Intramuscular
ARMsExperimental
DescriptionTBC-M4 at 0,1,6 months
Mode of DeliveryIntramuscular
ARMs
Official Code:
NCT00902824
Trial Sponsors:
IAVI
Start Date
End Date
November 30, 2008
April 30, 2010
Enrollment:32
Age range:
18 Years ↔
50 Years
Population: